Camrelizumab (INN; development code SHR-1210) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma. PD-1 is programmed cell death protein 1.
The drug is being developed by Jiangsu HengRui Medicine Co., Ltd. , camrelizumab is undergoing Phase II/III trials.
In China, in May 2025 camrelizumab was conditionally approved for use in combination with famitinib for the treatment of recurrent or metastatic cervical cancer in patients who have failed prior platinum-based chemotherapy and have not received prior bevacizumab.
Camrelizumab was approved in Russia in November 2024 under the brand name Areima. Its approved indications include certain forms of esophageal cancer, nasopharyngeal carcinoma, NSCLC, and TNBC.
References